高分辨率显微内镜改善食管癌筛查与监测:基于一项国际随机对照试验对资源匮乏全球环境的启示
这项国际随机对照试验在中国和美国纳入916名接受食管鳞状细胞癌筛查或监测者,随机接受卢戈氏染色内镜(LCE)或LCE+高分辨率显微内镜(HRME)。在筛查组中,HRME将诊断率从20.0%提高至51.7%,并可能减少65.2%的活检和59.7%参与者的任何活检。结论认为HRME联合LCE可提高筛查和监测效率,可能减少不必要的活检。
要点
- 筛查组中,HRME将诊断率从LCE的20.0%提高至LCE+HRME的51.7%。
- HRME可能减少65.2%的活检和59.7%参与者的任何活检。
- 6名参与者(0.7%)出现内镜医师在HRME上漏诊肿瘤(假阴性)。
核心结论
- 低成本显微内镜与LCE联合可提高食管鳞状细胞癌筛查和监测的效率与临床影响。
- HRME可能减少不必要的活检,在疾病流行的资源匮乏全球环境中带来成本节约。
研究设计与样本
- 国际随机对照试验,在中国和美国的多种临床环境中纳入接受专家和新手内镜医师筛查或监测食管鳞状细胞癌的个体。
- 参与者随机分配至LCE(标准治疗)或LCE+HRME(实验组),主要结局为使用金标准共识病理比较LCE与LCE+HRME的效率和临床影响。
- 共916名知情同意参与者,其中859名(93.8%)在中国招募,36名(3.9%)在美国;21名(2.3%)因操作或数据不完整被排除。
- 筛查组中,217名随机分配至LCE,204名至LCE+HRME;监测组中,236名随机分配至LCE,238名至LCE+HRME。
主要发现
- 筛查组中,诊断率(肿瘤性/总活检数)从LCE的20.0%(95%CI 12.7-29.2)提高至LCE+HRME的51.7%(95%CI 32.5-70.6)。
- HRME可能减少65.2%(95%CI 54.6-74.9)的活检和59.7%(95%CI 47.5-71.1)参与者的任何活检。
- 6名参与者(0.7%)出现内镜医师在HRME上漏诊肿瘤(假阴性),其中3例为新手漏诊的中度或高度异型增生。
局限性
- 6名参与者(0.7%)出现内镜医师在HRME上漏诊肿瘤(假阴性),其中3例为新手漏诊的中度或高度异型增生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lugol's chromoendoscopy (LCE)-based detection of esophageal squamous cell neoplasia (ESCN) is limited by low specificity. High-resolution microendoscopy (HRME) was shown to improve specificity and reduce unnecessary biopsies when used by academic endoscopists. In this international randomized controlled trial, we determined the clinical impact, efficiency, and performance of HRME in true global health contexts with a range of providers. METHODS: Individuals undergoing screening or surveillance for ESCN by expert and novice endoscopists were enrolled in China and the United States from diverse clinical settings. Participants were randomized to LCE (standard of care) or LCE + HRME (experimental). The primary outcomes were the efficiency and clinical impact of LCE vs LCE + HRME using gold-standard consensus pathology. RESULTS: Among 916 consented participants, 859 (93.8%) were recruited in China and 36 (3.9%) in the United States; 21 (2.3%) were excluded due to incomplete procedure or data. In the screening arm, 217 participants were randomized to LCE and 204 to LCE + HRME; in the surveillance arm, 236 were randomized to LCE and 238 to LCE + HRME. HRME increased efficiency in screening: diagnostic yield (neoplastic/total biopsies) improved from 20.0% (95% confidence interval [CI], 12.7-29.2) to 51.7% (95% CI, 32.5-70.6) with 65.2% (95% CI, 54.6-74.9) of biopsies potentially saved and 59.7% (95% CI, 47.5-71.1) of participants potentially spared any biopsy. Six participants (0.7%) had neoplasia missed by the endoscopist on HRME (false negatives); of these, 3 were moderate or high-grade dysplasia missed by novices. CONCLUSIONS: A low-cost microendoscope improves the efficiency and clinical impact of ESCN screening and surveillance when combined with LCE. HRME may spare unnecessary biopsies, leading to cost savings in underserved global settings where the disease is prevalent. (ClinicalTrials.gov, Number NCT02029937).
引用
- Tan MC, Li Z, Patel KK, et al. A High-Resolution Microendoscope Improves Esophageal Cancer Screening and Surveillance: Implications for Underserved Global Settings Based on an International Randomized Controlled Trial. Gastroenterology. 2024. PMID: 39477026. doi:10.1053/j.gastro.2024.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。